This was a major year for stem cells, as we saw the first ever induced pluripotent stem cell (iPSC) trial in humans, as well as several large mergers and acquisitions within the stem cell industry. One of the most prominent was the buyout of Life Technologies by industry behemoth Thermo Fisher Scientific.
There were also major technical advances that occurred, including notable advances made by scientists at the Harvard Stem Cell Institute (HSCI) toward the creation of human insulin-producing cells from human embryonic stem cells, as well as advances in the bio-fabrication of human tissues using 3-D cell printing technology, led by Guohao Dai of the Rensselaer Polytechnic Institute, among others.
As we head into the new year, most stem cell companies will be tasked with meeting increasingly large sales goals and implementing new strategies for company growth.
Specifically, you will need to:
- Make smarter decisions, faster
- Compete without the expense of new hires or a huge business development department
- Assess profitable opportunities within your market
- Develop high-demand products that will bring customers to you, instead of your competition
- Increase revenue within your organization
- Minimize risk by understanding competitive threats
As a research firm specializing in the stem cell sector, it is our mission to help you to achieve these goals. Among the clients that we advise, we repeatedly observed the value of market intelligence in allowing you to make informed, strategic decisions. While not all companies need this type of market guidance, it can be an accelerator for growth and profitability for some companies.
This is particularly true when disruptive technologies enter the market, such as when the technology for induced pluripotent stem cell (iPSC) creation emerged on the scene in 2006 out of Kyoto University. Global strategic insights for stem cell markets can also be helpful when market competition increases, as well as when the funding for stem cell related research becomes tightened at a federal or state level.
To accelerate your growth, explore our market research below:
- Global Cord Blood Banking Industry Report
The cord blood industry has matured substantially, creating serious threats and new opportunities. This report contains cord blood industry metrics, including clinical trial rates, patent rates, scientific publication rates, grant rates, and product launch trends, as well as survey findings from 600+ parents worldwide who reveal fears, expectations, and perceptions about cord blood banking. Read more… - Induced Pluripotent Stem Cell Industry Report
Several landmark events recently occurred within the iPSC market, making it clear that this is a lucrative product market. Furthermore, the number of iPSC products sold worldwide is growing at an annual rate of 14.7%, and 22% of stem cell researchers now report having used iPSCs within a research project. A distinctive feature of this report is a survey of 274 iPSC researchers (131 U.S. / 143 International) that reveals end-user needs, technical preferences, factors influencing purchasing decisions, and more. Read more… - Stem Cell Research Products – Opportunities, Tools, & Technologies
This report provides global strategies for the stem cell industry and identifies unique market opportunities by stem cell type (iPSC, MSC, NSC, ESC, and more). It contains metrics and trend rate data to help you to understand prevailing market conditions across the stem cell marketplace and guide you to strategically position your stem cell products. Read more…
- Global Cord Blood Banking Industry Report
As always, remember all of our market research is backed by a 60-Day Money Back Guarantee. If the strategies and tools aren’t helpful to you – we’ll cheerfully refund your money and you can keep the product.
